CN105121437B - 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法 - Google Patents

香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法 Download PDF

Info

Publication number
CN105121437B
CN105121437B CN201480009649.8A CN201480009649A CN105121437B CN 105121437 B CN105121437 B CN 105121437B CN 201480009649 A CN201480009649 A CN 201480009649A CN 105121437 B CN105121437 B CN 105121437B
Authority
CN
China
Prior art keywords
compound
cftr
substituted
cell
dbm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480009649.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105121437A (zh
Inventor
E.施维伯特
J.施特雷夫
J.迪克松
H.高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Discoverybiomed Inc
Original Assignee
Discoverybiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discoverybiomed Inc filed Critical Discoverybiomed Inc
Publication of CN105121437A publication Critical patent/CN105121437A/zh
Application granted granted Critical
Publication of CN105121437B publication Critical patent/CN105121437B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201480009649.8A 2013-03-15 2014-03-14 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法 Expired - Fee Related CN105121437B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788353P 2013-03-15 2013-03-15
US61/788353 2013-03-15
PCT/US2014/027079 WO2014152213A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Publications (2)

Publication Number Publication Date
CN105121437A CN105121437A (zh) 2015-12-02
CN105121437B true CN105121437B (zh) 2018-12-04

Family

ID=51581684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480009649.8A Expired - Fee Related CN105121437B (zh) 2013-03-15 2014-03-14 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法

Country Status (9)

Country Link
US (1) US9815825B2 (https=)
EP (1) EP2970248B1 (https=)
JP (1) JP6514680B2 (https=)
KR (1) KR20150131309A (https=)
CN (1) CN105121437B (https=)
AU (1) AU2014240026B2 (https=)
CA (1) CA2903103C (https=)
MX (1) MX372775B (https=)
WO (1) WO2014152213A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158913A2 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
EP2922852A4 (en) 2012-11-20 2016-05-25 Discoverybiomed Inc SMALL MOLECULAR CFTR CORRECTORS
US9546176B2 (en) 2012-11-20 2017-01-17 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic CFTR correctors
KR20150132483A (ko) * 2013-03-15 2015-11-25 디스커버리바이오메드 인코포레이티드 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
MA43775A (fr) 2016-04-07 2021-05-05 Proteostasis Therapeutics Inc Analogues du ivacaftor conentant des atomes de silicium
MA45397A (fr) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
AU2017348186A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating CFTR
CA3041675A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
MA49061A (fr) 2017-04-28 2021-04-21 Proteostasis Therapeutics Inc Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
AU2018346602B2 (en) 2017-10-06 2024-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing CFTR activity
WO2019136314A1 (en) 2018-01-05 2019-07-11 The Curators Of The University Of Missouri Compounds and methods for treatment of cystic fibrosis
AU2019334684B2 (en) 2018-09-09 2025-03-06 Qanatpharma Ag Use of CFTR modulators for treating cerebrovascular conditions
CN110156761B (zh) * 2019-06-18 2022-08-09 郑州大学 含香豆素-联苯骨架化合物、制备方法及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
WO2003066630A2 (en) * 2002-02-07 2003-08-14 Amgen Inc. Quinolinone derivatives for treating cell proliferation related disorders
CN101039919A (zh) * 2004-10-13 2007-09-19 惠氏公司 经n－苯磺酰基取代的苯胺基嘧啶类似物
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
WO2009076665A1 (en) * 2007-12-13 2009-06-18 Indiana University Research And Technology Corporation Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
WO2012171954A1 (en) * 2011-06-14 2012-12-20 Azienda Ospedaliera Universitaria Integrata Di Verona Trimethylangelicin as cftr corrector in bronchial epithelial cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) * 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
AU2003245935A1 (en) 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
EP1799659A1 (en) * 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
US20090012148A1 (en) * 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
KR20150132483A (ko) 2013-03-15 2015-11-25 디스커버리바이오메드 인코포레이티드 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
WO2003066630A2 (en) * 2002-02-07 2003-08-14 Amgen Inc. Quinolinone derivatives for treating cell proliferation related disorders
CN101039919A (zh) * 2004-10-13 2007-09-19 惠氏公司 经n－苯磺酰基取代的苯胺基嘧啶类似物
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
WO2009076665A1 (en) * 2007-12-13 2009-06-18 Indiana University Research And Technology Corporation Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
WO2012171954A1 (en) * 2011-06-14 2012-12-20 Azienda Ospedaliera Universitaria Integrata Di Verona Trimethylangelicin as cftr corrector in bronchial epithelial cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
4(3"-Coumarinyl)-2-Arylamino Thiazoles and some of their derivatives;A.K.Panigrahi，等;《Indian Chem. Soc.》;19711231;第48卷(第7期);第666页Table I *
A Combination Strategy to Inhibit Pim-1: Synergism between Noncompetitive and ATP-Competitive Inhibitors;Mattia Mori，等;《ChemMedChem》;20130222;第8卷;第489页图4 *
A Convenient, Rapid and Eco-Friendly Synthesis of Isoxazoline Heterocyclic Moiety Containing Bridge at 2°-Amine as Potential Pharmacological Agent;J.T. Desai，等;《J. Iran. Chem. Soc.》;20080331;第5卷(第1期);第68页Scheme 1 *
Double Functional Group Transformations for Fluorescent Probe Construction: A Fluorescence Turn-On Probe for Thioureas;Weiying Lin，等;《Chemistry A European Journal》;20100611;第16卷(第22期);第6455页 Scheme 1 *
Intramolecular Amidation: Synthesis of Novel Thiazole‐Fused Diazepinones;Rajesh S. Koti，等;《Synthetic Communications》;20070725;第37卷(第1期);第100页Scheme 1 *
RN:313954-56-2, 313954-55-1, 724744-64-3, 403721-74-4, 403721-73-3, 325804-07-7, 325804-06-6, 325473-18-5, 312703-21-2;ACS;《STN Registry数据库》;20040810 *
Stimulation of airway and intestinal mucosal secretion by natural coumarin CFTR activators;Hong Yang，等;《Frontiers in Pharmacology》;20110927;第2卷;第1-5页 *
Synthesis and evaluation of some substituted 2-arylamino coumarinyl Thiazoles as potential NSDAIDS;K.N. Venugopala，等;《Asian Journal of Chemistry》;20041231;第16卷(第2期);第873页Scheme1中5a-v，第875页表1 *
Synthesis of some new type of thiazolyl coumarins;K Srimanth，等;《Indian Asian Journal of Chemistry》;19990430;第38B卷(第4期);第473-475页 *

Also Published As

Publication number Publication date
EP2970248A4 (en) 2017-01-11
US9815825B2 (en) 2017-11-14
JP6514680B2 (ja) 2019-05-15
AU2014240026B2 (en) 2018-06-14
KR20150131309A (ko) 2015-11-24
WO2014152213A2 (en) 2014-09-25
AU2014240026A1 (en) 2015-08-20
CN105121437A (zh) 2015-12-02
MX372775B (es) 2020-06-29
JP2016515131A (ja) 2016-05-26
WO2014152213A3 (en) 2014-11-13
CA2903103C (en) 2020-06-09
HK1218420A1 (en) 2017-02-17
CA2903103A1 (en) 2014-09-25
US20160024065A1 (en) 2016-01-28
MX2015013173A (es) 2016-04-04
EP2970248A2 (en) 2016-01-20
EP2970248B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
CN105121437B (zh) 香豆素衍生物和用于治疗囊性纤维化、慢性阻塞性肺病和错误折叠蛋白质病症的方法
CN107205961B (zh) 酚类trpv1激动剂的前药
CA2891962A1 (en) Small molecule cftr correctors
US20150307503A1 (en) Small molecule bicyclic and tricyclic cftr correctors
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
JP2007517887A (ja) アザベンゾフラン置換されたチオ尿素、ウイルス複製のインヒビター
JP2021528470A (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN108848668B (zh) Cftr调节剂及其使用方法
CN107793408A (zh) 哌啶氨基衍生物及其治疗精神分裂症的应用
TW201522291A (zh) 胍基苯甲酸酯化合物
CN113166051A (zh) 酚类trpv1激动剂的聚乙二醇化前药
CN107793350A (zh) 芳乙基哌啶基衍生物及其治疗精神分裂症的应用
EP2070908A1 (en) Compound having benzamide skeleton and cyclooxygenase (cox-1)-selective inhibitory activity
AU2020290094B2 (en) Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
EP4477642A1 (en) Crystal form of cyclohexenone compound
HK40059345A (en) Pegylated prodrugs of phenolic trpv1 agonists
CN120569387A (zh) Par2的小分子调节剂及其用途
CN113825758A (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
HK1218420B (en) Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
CA2920315A1 (en) Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181204